Windlas Biotech Ltd: 795 Cr Sales, 7k Product Licenses, and Still Injecting Hopes into Investors
1. At a Glance
Windlas Biotech is that CDMO kid in pharma class who doesn’t make blockbuster drugs of its own, but happily manufactures them for the toppers. With five WHO-GMP plants in Dehradun, a brand list longer than Bollywood remake announcements, and a shiny new injectables facility about to go live, Windlas has all the buzzwords: complex generics, chronic therapies, EU-GMP, SAPHRA, USFDA dreams. Market cap ₹2,140 Cr, P/E 33x, and still — ROE just 12.8%. Matlab, decent marks, but not yet class monitor.
2. Introduction
The pharma game is divided into two types of players:
The Big Bosses (Sun, Cipla, Dr Reddy’s) — who own IPs, brands, and global distribution.
The Silent Sidekicks (Windlas-type CDMOs) — who do all the manufacturing jugaad and still get called “service providers.”
Windlas has chosen to be a sidekick with style. Instead of wasting billions on risky drug research, it rents out its factories to top Indian pharma names — Pfizer, Sanofi, Zydus, Cadila, Eris, Intas, etc. In FY24, 64% of its products were complex generics — aka the difficult recipes where margins are tastier. Chronic therapy focus (anti-diabetic, cardiovascular, neuropsychiatry) gives steady demand, unlike seasonal cough syrups.
But there are trade-offs:
Top customer contribution has fallen from 57% (FY20) to 35.5% (FY24). Good risk management, or simply client diversification forced by overdependence?
Exports are just 4% of sales — Windlas dreams global, but right now it’s basically Dehradun to Delhi supply chain.
3. Business Model (WTF Do They Even Do?)
a) Generic Formulations CDMO (75% of revenue):
Tablets, capsules, sachets, powders.
Manufacture + development services.
Windlas doesn’t own the products (99% IPs belong to clients). It’s like being a Bollywood ghost singer — voice is yours, credit goes elsewhere.
b) Trade Generics & Institutional (21%):
280 brands sold via 996 distributors across 29 states.
Low-cost meds for Jan Aushadhi Yojana & semi-urban India.
Basically, “Chhota Chetan” of pharma — affordable but effective.
c) Exports (4%):
69 products shipped to semi-regulated markets.
Got SAPHRA (South Africa) and EU-GMP approvals, aiming for USFDA.
Still early innings — like Virat Kohli before 2008 IPL.
4. Financials Overview
Latest Quarterly Snapshot (Jun 2025 vs Jun 2024 & Mar 2025)
Source table
Metric
Jun 2025
Jun 2024
Mar 2025
YoY %
QoQ %
Revenue (₹ Cr)
210
175
203
20.0%
3.4%
EBITDA (₹ Cr)
27
21
26
28.6%
3.8%
PAT (₹ Cr)
17.7
13.5
16.1
31.0%
9.9%
EPS (₹)
8.45
6.45
7.79
31.0%
8.5%
Commentary: Growth is consistent, margins holding steady ~13%. EPS annualised = ₹34 → P/E recalculated = 30.1x (vs official 32.8x). Not dirt cheap, but at least not Voltas-level ridiculous.
5. Valuation – Fair Value Range
P/E Method EPS = ₹34 Industry P/E = 33 FV Range = ₹34 × 25–33 → ₹850 – ₹1,120
